Souleymane TASSEMBEDO

Dr. Souleymane TASSEMBEDO


Research Focus & Metrics

Academic Career Length

8Years (2019-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
14 June 2019 in Viruses
Verified
Journal Article
Open access
PDF file
CDChloe Dimeglio
Chloe Dimeglio
DKDramane Kania
Dramane Kania
MJMantono judith
Mantono judith
TKThérèse Kagoné
Thérèse Kagoné
SZSylvie Zida
Sylvie Zida
JIJacques Izopet
Jacques Izopet
Hepatitis E virus infection is a significant public health problem in many parts of the world including Africa. We tested serum samples from 900 patients in Burkina Faso presenting with febrile icterus. They all tested negative for yellow fever, but those from 23/900 (2.6%) patients contained markers of acute HEV infection (anti-HEV IgM and HEV RNA positive). Genotyping indicated that 14 of the strains were HEV genotype 2b. There was an overall HEV IgG seroprevalence of 18.2% (164/900). In a bivariate analysis, the factors linked to HEV exposure were climate and patient age. Older patients and those living in arid regions were more likely to have HEV infection. HEV genotype 2b circulating only in humans can be involved in some acute febrile icterus cases in Burkina Faso. Better access to safe water, sanitation, and improved personal hygiene should improve control of HEV infection in this country.

4 January 2024 in AIDS
Verified
Journal Article
Open access
STSouleymane TASSEMBEDO
Souleymane TASSEMBEDO
MMMwiya Mwiya
Mwiya Mwiya
AMAnais Mennecier
Anais Mennecier
CKChipepo Kankasa
Chipepo Kankasa
PFPaulin Fao
Paulin Fao
FGfor the PROMISE-EPI Study Group∗
for the PROMISE-EPI Study Group∗
Objective: Our study aimed to assess the PMTCT indicators in Burkina Faso and Zambia using a patient-orientated innovative strategy based on the second visit in the Expanded Program on Immunization (EPI-2) visit at 6–8 weeks. Design: This was a cross sectional study. Methods: We assessed women attending EPI-2 at primary healthcare facilities in Burkina Faso and Zambia with their children about their exposure to PMTCT interventions. For women living with HIV (WLHIV), viral load was measured and their children were tested for HIV DNA using point of care devices. Results: Overall, 25 093 were enrolled from Burkina Faso and 8961 women from Zambia. Almost, all women attended at least one antenatal care visit. Among those aware of their HIV-positive status, 95.8 and 99.2% were on antiretroviral therapy (ART) in Burkina Faso and Zambia, respectively. Among WLHIV on ART, 75 and 79.2% achieved a viral load suppression (viral load <1000 copies/ml) in Burkina Faso and Zambia, respectively. Infant postnatal prophylaxis was administered from birth until EPI-2 to 60.9 and 89.7% of HIV-exposed children in Burkina Faso and Zambia, respectively. In Burkina Faso, only 60 of 192 (31.3%) of HIV-exposed children were sampled at day 42 for early infant diagnosis (EID) and 3 (1.6%) received a result by EPI-2. In Zambia, these figures were 879 of 1465 (64.0%) and 9.9% (145/1465), respectively for HIV-exposed children sampled at birth. Conclusion: This evaluation strategy at EPI-2 visit could strengthen program monitoring and help identifying gaps to be addressed on the last mile towards elimination of MTCT of HIV.

1 January 2023 in Pan African Medical Journal
Verified
Journal Article
Open access
STSouleymane TASSEMBEDO
Souleymane TASSEMBEDO
CWChristian Henrik Winter
Christian Henrik Winter
ITIsidore Tiandogo Traore
Isidore Tiandogo Traore
AOAdama Ouattara
Adama Ouattara
MSMamadou Sawadogo
Mamadou Sawadogo
NMNicolas Meda
Nicolas Meda
INTRODUCTION: Cervical cancer is a major public health problem among women in sub-Saharan Africa. The disease can be controlled through early diagnosis through simple cost-effective methods such as visual inspection of the cervix after application of acetic acid or lugol's iodine. However, screening for cervical cancer is still underused particularly in rural areas of Burkina Faso. The objective were to estimate the prevalence of cervical pre-cancer cancer in rural health district of Boussé, Burkina Faso. METHODS: we conducted a cross-sectional study in the health district of Boussé in Northern-Central Burkina Faso from July to August 2014. Women aged 23-50 years were interviewed about their knowledge of cervical cancer and their screening practice and subsequently screened for cervical cancer by VIA. RESULTS: a total of 418 participants were included with a median age of 34 years IQR (30-40 years). Two² hundred participants (48%) had never heard about cervical cancer. About 134 participants (32%) knew at least one risk factor of cervical cancer. Only 37 women (9%) reported ever been screened for cervical cancer. Twenty-two percent reported concurrent sexual partnerships. The majority of the women (92%) are willing to pay to get screened for cervical pre-cancer by VIA. Overall, 21 participants (5%) were diagnosed with a cervical lesion by VIA and all of them accepted treatment with Loop electro surgical procedure. CONCLUSION: screening by VIA is feasible in rural Burkina Faso, but there is a poor knowledge on cervical cancer amongst the women. There is a need to set up a comprehensive, systematic, affordable and efficient cervical cancer program including an information campaign and making screening accessible in rural remote areas.

24 April 2025 in The Lancet HIV
Verified
Journal Article
Closed access
STSouleymane TASSEMBEDO
Souleymane TASSEMBEDO
NMNicolas Meda
Nicolas Meda
CKChipepo Kankasa
Chipepo Kankasa
RSRoger Shapiro
Roger Shapiro
TRTheodore Ruel
Theodore Ruel
NNNicolas Nagot
Nicolas Nagot

27 June 2025 in Journal of Virus Eradication
Verified
Journal Article
Open access
AKAude Christelle Ka'e
Aude Christelle Ka'e
CACollins Chenwi Ambe
Collins Chenwi Ambe
FLForgu Esemu Livo
Forgu Esemu Livo
HTHillary Tene
Hillary Tene
RDRomeo Djounda
Romeo Djounda
JFJoseph Fokam
Joseph Fokam
Despite global efforts to eliminate HIV as a public health threat, sub-Saharan Africa (SSA) still harbours about the highest burden of the pandemic, home to around 70 % of people living with HIV with limited contribution in the field of HIV cure research, especially in West and Central Africa (WCA). This gap is mainly due to challenges that researchers of this region are facing in initiating and advancing HIV cure research locally, with lesser commitment from the French-speaking countries. Furthermore, capacity-building of early career scientists on HIV cure research remains constrained due to limited awareness and language barriers to existing opportunities. Even though HIV non-B subtypes represent 89 % of circulating subtypes worldwide, cure research has been extensively focused on subtype B (prevalent in America and Europe). Interestingly, WCA (known as HIV pandemic epicentre with a broad genetic diversity) offers a unique landscape for cure research with a likelihood of generalisability across various HIV subtypes. This viewpoint discusses the importance of establishing an HIV Cure Academy for WCA to support scientists, policymakers and community stakeholders from French-speaking countries in contributing to the global efforts towards HIV cure.

1 March 2024 in Bulletin of the World Health Organization
Verified
Journal Article
Open access
STSouleymane TASSEMBEDO
Souleymane TASSEMBEDO
ITIsidore Tiandiogo Traoré
Isidore Tiandiogo Traoré
MTMakoura Traoré-Barro
Makoura Traoré-Barro
IDIsmael Diallo
Ismael Diallo
DMDaoudaq Maré
Daoudaq Maré
NNNicolas Nagot
Nicolas Nagot
To estimate the feasibility, positivity rate and cost of offering child testing for human immunodeficiency virus (HIV) to mothers living with HIV attending outpatient clinics in Burkina Faso. We conducted this implementation study in nine outpatient clinics between October 2021 and June 2022. We identified all women ≤ 45 years who were attending these clinics for their routine HIV care and who had at least one living child aged between 18 months and 5 years whose HIV status was not known. We offered these mothers an HIV test for their child at their next outpatient visit. We calculated intervention uptake, HIV positivity rate and costs. Of 799 eligible children, we tested 663 (83.0%) and identified 16 new HIV infections: 2.5% (95% confidence interval, CI: 1.5-4.1). Compared with HIV-negative children, significantly more HIV-infected children were breastfed beyond 12 months (P-value: 0.003) and they had not been tested before (P-value: 0.003). A significantly greater proportion of mothers of HIV-infected children were unaware of the availability of child testing at 18 months (P-value: < 0.001) and had more recently learnt their HIV status (P-value: 0.01) than mothers of HIV-negative children. The intervention cost 98.1 United States dollars for one child testing HIV-positive. Barriers to implementing this strategy included shortages of HIV tests, increased workload for health-care workers and difficulty accessing children not living with their mothers. Testing HIV-exposed children through their mothers in outpatient clinics is feasible and effective in a low HIV-prevalence setting such as Burkina Faso. Implementation of this strategy to detect undiagnosed HIV-infected children is recommended.